基于前哨淋巴结活检指导的个性化颈部照射用于临床阴性颈的口咽、喉或下咽鳞状细胞癌患者:(放)化疗仅照射原发肿瘤的PRIMO研究方案
PRIMO研究是一项多中心随机对照试验,旨在比较前哨淋巴结活检指导的颈部照射与标准双侧选择性颈部照射在cN0口咽、喉或下咽鳞状细胞癌患者中的安全性和有效性。试验纳入242例患者,主要安全终点为治疗后2年内区域淋巴结复发患者数,主要疗效终点为治疗后6个月患者报告的口干相关生活质量。
要点
- PRIMO研究比较前哨淋巴结活检指导的个性化颈部照射与标准双侧选择性颈部照射。
- 试验纳入242例cN0口咽、喉或下咽鳞状细胞癌需双侧选择性颈部照射的患者。
- 主要安全终点为治疗后2年内区域淋巴结复发患者数,主要疗效终点为6个月口干相关生活质量。
核心结论
- 若试验证明试验组治疗在区域复发方面非劣于标准治疗且口干相关生活质量更优,则将成为新的标准治疗。
研究设计与样本
- 多中心随机对照试验,纳入242例cN0口咽、喉或下咽鳞状细胞癌且需双侧选择性颈部照射的患者。
- 试验组行前哨淋巴结活检,根据前哨淋巴结病理状态决定不接受选择性颈部照射(全部阴性)、单侧颈部照射(一侧阳性)或双侧颈部照射(双侧阳性)。
- 对照组不行前哨淋巴结活检,接受标准双侧选择性颈部照射。
主要发现
- 主要安全终点为治疗后2年内区域淋巴结复发患者数。
- 主要疗效终点为治疗后6个月患者报告的口干相关生活质量。
- 预期10例患者中9例可省略一侧或双侧颈部选择性照射,从而减少放疗副作用并提高生活质量。
关键数值与推荐
- 试验组根据前哨淋巴结活检结果决定颈部照射范围:全部阴性不接受选择性颈部照射,一侧阳性行单侧颈部照射,双侧阳性行双侧颈部照射。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Elective neck irradiation (ENI) is performed in head and neck cancer patients treated with definitive (chemo)radiotherapy. The aim is to eradicate nodal metastases that are not detectable by pretreatment imaging techniques. It is conceivable that personalized neck irradiation can be performed guided by the results of sentinel lymph node biopsy (SLNB). It is expected that ENI can be omitted to one or both sides of the neck in 9 out of 10 patients, resulting in less radiation side effects with better quality of life. METHODS/DESIGN: This is a multicenter randomized controlled trial aiming to compare safety and efficacy of treatment with SLNB guided neck irradiation versus standard bilateral ENI in 242 patients with cN0 squamous cell carcinoma of the oropharynx, larynx or hypopharynx for whom bilateral ENI is indicated. Patients randomized to the experimental-arm will undergo SLNB. Based on the histopathologic status of the SLNs, patients will receive no ENI (if all SLNs are negative), unilateral neck irradiation only (if a SLN is positive at one side of the neck) or bilateral neck irradiation (if SLNs are positive at both sides of the neck). Patients randomized to the control arm will not undergo SLNB but will receive standard bilateral ENI. The primary safety endpoint is the number of patients with recurrence in regional lymph nodes within 2 years after treatment. The primary efficacy endpoint is patient reported xerostomia-related quality of life at 6 months after treatment. DISCUSSION: If this trial demonstrates that the experimental treatment is non-inferior to the standard treatment in terms of regional recurrence and is superior in terms of xerostomia-related quality of life, this will become the new standard of care.
引用
- van den Bosch S, Takes RP, de Ridder M, et al. Personalized neck irradiation guided by sentinel lymph node biopsy in patients with squamous cell carcinoma of the oropharynx, larynx or hypopharynx with a clinically negative neck: (Chemo)radiotherapy to the PRIMary tumor only. Protocol of the PRIMO study. Clin Transl Radiat Oncol. 2023. PMID: 37965060. doi:10.1016/j.ctro.2023.100696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。